Objective: To investigate the inherited mutations and their association with clinical features and treatment response in young-onset prostate cancer patients.
Method: Targeted gene sequencing on 139 tumor susceptibility genes was conducted with a total of 24 patients diagnosed with PCa under the age of 63 years old. Meanwhile, the related clinical information of those patients is collected and analyzed.
Results: Sixty-two germline mutations in 45 genes were verified in 22 patients.
Conclusion: Mutations in DRGs are more prevalent in early-onset PCa with advanced clinical stages, and these patients had shorter progression-free survival. ADT Combined with either radiotherapy or chemotherapy may be effective in treating PCa caused by HRR-related gene mutations.
Frontiers in Oncology
Tang, Tang; Tan, Xintao; Wang, Ze; Wang, Shuo; Wang, Yapeng; Xu, Jing; Wei, Xiajie; Zhang, Dianzheng; Liu, Qiuli; and Jiang, Jun, "Germline Mutations in Patients With Early-Onset Prostate Cancer." (2022). PCOM Scholarly Papers. 2161.